Colchicine for cardiovascular and limb risk reduction in Medicare beneficiaries with peripheral artery disease: emulation of target trials.
Patrick HeindelJames J FitzgibbonEric A SecemskyDeepak L BhattMohammed Al-OmranSubodh VermaIbrahim A AlmaghlouthArin L MadenciMohamad A HussainPublished in: European heart journal open (2024)
In a real-world sample of patients with PAD and gout, estimates of the effect of colchicine were consistent across two analyses and provided no conclusive evidence that colchicine decreased the risk of adverse cardiovascular or limb events and death. The cardiovascular and limb benefits of colchicine in older, comorbid populations with PAD and advanced systematic atherosclerosis remain uncertain.